RxDoctor Payments Data

Joseph Folz, DO

Pain Medicine · Evansville, INNPI 1881013647

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,450 of the $5,410 with a category attached, or 82.3%. 29 manufacturers reported payments, led by Abbott at 53.1% of the total. Reporting peaked in 2019 at $1,568 and has fallen 70.3% since, to $466 in 2025.

$5,410in general payments, 2019–2025

Across 232 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • AbbVie$859
  • Amgen$492
  • Vertos Medical, Inc.$130
  • Nevro Corp.$112
  • Biohaven Pharmaceutical Holding Company Ltd.$108
  • plus $839 from 23 others

What the payments were for

  • Travel & lodging$96018%
  • Food & beverage$4,45082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,410 in reported general payments places this provider in the 65th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$1,136,519
Medicare patients
1,782
Services billed
19,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl74$51,123
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,139$31,956
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,464$31,592
Buprenorphine76$23,075
OxycontinOxycodone Hcl24$20,086
Fentanyl48$6,737
Gabapentin499$6,143
Pregabalin184$5,481
Oxycodone Hcl193$5,303
Hydromorphone Hcl131$2,772
AmantadineAmantadine Hcl16$2,070
Morphine Sulfate ErMorphine Sulfate54$1,868
Lidocaine17$1,510
Tramadol Hcl163$1,150
Tizanidine Hcl123$887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$53$51,12374 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →